Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,273,812 papers from all fields of science
Search
Sign In
Create Free Account
Cancer and Leukemia Group B
Known as:
CALGB
A national clinical research group - network of 29 university medical centers, over 185 community hospitals and more than almost 3000 physicians…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Source of protocol in which patient enrolled:Type:Pt:Cancer.XXX:Nom
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage…
W. Sikov
,
D. Berry
,
+14 authors
E. Winer
Journal of Clinical Oncology
2015
Corpus ID: 26954488
PURPOSE One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard…
Expand
Highly Cited
2013
Highly Cited
2013
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
K. Hughes
,
L. Schnaper
,
+8 authors
W. Wood
Journal of Clinical Oncology
2013
Corpus ID: 207033627
PURPOSE To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in…
Expand
Highly Cited
2010
Highly Cited
2010
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
H. Kindler
,
D. Niedzwiecki
,
+12 authors
R. Goldberg
Journal of Clinical Oncology
2010
Corpus ID: 21617350
PURPOSE The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a…
Expand
Highly Cited
2008
Highly Cited
2008
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North…
G. Strauss
,
J. Herndon
,
+9 authors
Mark R. Green
Journal of Clinical Oncology
2008
Corpus ID: 37433961
PURPOSE Adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized…
Expand
Highly Cited
2008
Highly Cited
2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
J. Tepper
,
M. Krasna
,
+7 authors
R. Mayer
Journal of Clinical Oncology
2008
Corpus ID: 24767638
PURPOSE The primary treatment modality for patients with carcinoma of the esophagus or gastroesophageal junction has been surgery…
Expand
Highly Cited
2007
Highly Cited
2007
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
H. Muss
,
D. Berry
,
+6 authors
C. Hudis
Journal of Clinical Oncology
2007
Corpus ID: 45475493
PURPOSE Older node-positive patients treated with newer adjuvant chemotherapy regimens have improvements in relapse-free and…
Expand
Highly Cited
2006
Highly Cited
2006
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
J. Meyerhardt
,
D. Heseltine
,
+9 authors
C. Fuchs
Journal of Clinical Oncology
2006
Corpus ID: 24886310
PURPOSE Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with…
Expand
Highly Cited
1999
Highly Cited
1999
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.
M. Wetzler
,
R. Dodge
,
+11 authors
C. Bloomfield
Blood
1999
Corpus ID: 23630126
The Cancer and Leukemia Group B (CALGB) has been conducting a prospective cytogenetic companion study (CALGB 8461) to all CALGB…
Expand
Highly Cited
1998
Highly Cited
1998
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon
,
Mark R. Green
,
A. Chahinian
,
J. Corson
,
Yasunosuke Suzuki
,
N. Vogelzang
Chest
1998
Corpus ID: 12307742
PURPOSE To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients…
Expand
Highly Cited
1996
Highly Cited
1996
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
R. Dillman
,
J. Herndon
,
S. Seagren
,
W. Eaton
,
Mark R. Green
Journal of the National Cancer Institute
1996
Corpus ID: 37605659
BACKGROUND For many years, high dose radiation therapy was the standard treatment for patients with locally or regionally…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE